Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPG NASDAQ:AUTL NASDAQ:HROW NASDAQ:SLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$16.77-1.6%$20.22$16.36▼$48.45$1.59B-0.0510,236 shs195,418 shsAUTLAutolus Therapeutics$1.63+2.2%$1.60$1.18▼$2.70$423.19M2.021.20 million shs765,841 shsHROWHarrow$42.07+1.4%$37.05$28.54▼$54.85$1.55B0.28775,107 shs1.52 million shsSLSSELLAS Life Sciences Group$12.39+17.7%$7.14$1.39▼$12.43$2.07B2.58.04 million shs20.81 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International-1.64%-2.04%-18.49%-26.95%-58.06%AUTLAutolus Therapeutics+2.20%+7.62%-3.27%+34.30%-29.96%HROWHarrow+1.37%-1.87%+22.19%+24.36%+33.34%SLSSELLAS Life Sciences Group+17.66%+53.91%+44.41%+184.17%+569.73%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$16.77-1.6%$20.22$16.36▼$48.45$1.59B-0.0510,236 shs195,418 shsAUTLAutolus Therapeutics$1.63+2.2%$1.60$1.18▼$2.70$423.19M2.021.20 million shs765,841 shsHROWHarrow$42.07+1.4%$37.05$28.54▼$54.85$1.55B0.28775,107 shs1.52 million shsSLSSELLAS Life Sciences Group$12.39+17.7%$7.14$1.39▼$12.43$2.07B2.58.04 million shs20.81 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International-1.64%-2.04%-18.49%-26.95%-58.06%AUTLAutolus Therapeutics+2.20%+7.62%-3.27%+34.30%-29.96%HROWHarrow+1.37%-1.87%+22.19%+24.36%+33.34%SLSSELLAS Life Sciences Group+17.66%+53.91%+44.41%+184.17%+569.73%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.20Buy$46.43176.85% UpsideAUTLAutolus Therapeutics 2.89Moderate Buy$8.75438.46% UpsideHROWHarrow 2.64Moderate Buy$69.4365.03% UpsideSLSSELLAS Life Sciences Group 2.00Hold$10.00-19.29% DownsideCurrent Analyst Ratings BreakdownLatest AUTL, AAPG, HROW, and SLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2026AUTLAutolus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/15/2026AAPGAscentage Pharma Group International BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$48.006/10/2026AAPGAscentage Pharma Group International Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/10/2026AAPGAscentage Pharma Group International B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.005/29/2026AUTLAutolus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/14/2026AUTLAutolus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026AUTLAutolus Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $10.005/13/2026HROWHarrow Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$91.00 ➝ $88.005/12/2026HROWHarrow BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$63.004/29/2026AUTLAutolus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/24/2026AAPGAscentage Pharma Group International Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.00(Data available from 6/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$574.12M2.73N/AN/A$2.04 per share8.22AUTLAutolus Therapeutics$75.39M5.74N/AN/A$0.67 per share2.43HROWHarrow$272.30M5.76$0.88 per share48.02$1.41 per share29.84SLSSELLAS Life Sciences GroupN/AN/AN/AN/A$0.46 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group International-$177.71MN/AN/AN/AN/AN/AN/AN/AN/AAUTLAutolus Therapeutics-$287.53M-$1.09N/AN/AN/A-311.98%-128.59%-46.25%8/11/2026 (Estimated)HROWHarrow-$5.14M-$0.41N/A19.48N/A-5.57%19.59%2.26%8/10/2026 (Estimated)SLSSELLAS Life Sciences Group-$26.86M-$0.23N/AN/AN/AN/A-47.12%-42.63%8/11/2026 (Estimated)Latest AUTL, AAPG, HROW, and SLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026AUTLAutolus Therapeutics-$0.29-$0.27+$0.02-$0.27$26.27 million$26.22 million5/12/2026Q1 2026SLSSELLAS Life Sciences Group-$0.06-$0.05+$0.01-$0.05N/AN/A5/11/2026Q1 2026HROWHarrow-$0.43-$0.74-$0.31-$0.74$52.43 million$44.20 million3/27/2026Q4 2025AUTLAutolus Therapeutics-$0.27-$0.34-$0.07-$0.34$23.92 million$24.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AAUTLAutolus TherapeuticsN/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group International0.571.791.77AUTLAutolus TherapeuticsN/A5.805.28HROWHarrow10.302.482.30SLSSELLAS Life Sciences GroupN/A17.2217.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/AAUTLAutolus Therapeutics72.83%HROWHarrow72.76%SLSSELLAS Life Sciences Group17.38%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/AAUTLAutolus Therapeutics25.70%HROWHarrow12.80%SLSSELLAS Life Sciences Group1.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60093.39 millionN/AN/AAUTLAutolus Therapeutics330266.16 million197.75 millionOptionableHROWHarrow18037.28 million32.50 millionOptionableSLSSELLAS Life Sciences Group10196.63 million194.08 millionNot OptionableAUTL, AAPG, HROW, and SLS HeadlinesRecent News About These CompaniesSellas Life Sciences: The AML Platform Is More Interesting Than The Binary EventJune 27 at 5:02 AM | seekingalpha.comSELLAS Life Sciences jumps as traders focus on imminent REGAL trial catalyst and stronger cash positionJune 26 at 5:30 PM | quiverquant.comQSELLAS stock hits new highs: What's happening today?June 26 at 3:26 PM | msn.comWhat's driving SLS stock higher today and what comes next?June 26 at 12:30 PM | invezz.comISLS Short Interest Hits All-Time High: Sellas Bulls Smell A Short Squeeze As Executive Contract Changes Fuel Buyout ChatterJune 26 at 10:03 AM | finance.yahoo.comSellas (SLS) Extends Rally, New Filing Hints at Company TakeoverJune 26 at 5:02 AM | insidermonkey.comSLS stock up 13% as executive severance updates reignite buyout speculationJune 25 at 5:28 PM | msn.comSLS stock slips overnight: Shareholders approve 20M new shares, CEO awarded 1M RSUsJune 22, 2026 | msn.comWhat Does Strong Shareholder Support Mean for SELLAS Life Sciences Group (NASDAQ:SLS)?June 19, 2026 | kalkinemedia.comKSELLAS Stockholders Approve Governance and Equity Plan ChangesJune 18, 2026 | tipranks.comAnalyzing SELLAS Life Sciences Group (NASDAQ:SLS) and LENZ Therapeutics (NASDAQ:LENZ)June 17, 2026 | americanbankingnews.comAll eyes on SLS stock ahead of annual shareholder meet – what's on the agenda?June 16, 2026 | msn.comSLS Stock Slides Premarket: Traders Brace For Key Arbitration Ruling In GPS China Payment DisputeJune 5, 2026 | finance.yahoo.comSELLAS Life Sciences boosts liquidity through warrant exercisesJune 2, 2026 | tipranks.comJim Cramer on SELLAS: “It’s a Great Spec”June 1, 2026 | insidermonkey.comSELLAS Life Sciences Group (SLS) Is Up 21.4% After REGAL Nears Topline Readout And Cramer EndorsementMay 30, 2026 | finance.yahoo.comSLS Stock Extends Rally Overnight: CEO Says ‘Bullish’ Leukemia Data Could Drive NCCN Recognition For GPSMay 28, 2026 | finance.yahoo.comSellas Life Sciences: The Internal Inconsistency Of An Assumed Positive REGAL ReadoutMay 28, 2026 | seekingalpha.comSLS stock surges toward fifth weekly rise: CEO touts GPS as lifeline for elderly patients as cancer summit loomsMay 27, 2026 | msn.comSLS Stock Heads For Its Best Month This Year Ahead Of Key AML Trial ReadoutMay 26, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAUTL, AAPG, HROW, and SLS Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$16.77 -0.28 (-1.64%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$16.65 -0.12 (-0.72%) As of 06/26/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.Autolus Therapeutics NASDAQ:AUTL$1.62 +0.04 (+2.20%) Closing price 06/26/2026 03:59 PM EasternExtended Trading$1.60 -0.02 (-1.54%) As of 06/26/2026 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Harrow NASDAQ:HROW$42.07 +0.57 (+1.37%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$41.62 -0.45 (-1.08%) As of 06/26/2026 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.SELLAS Life Sciences Group NASDAQ:SLS$12.39 +1.86 (+17.66%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$12.22 -0.18 (-1.41%) As of 06/26/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/22 - 06/26 Rocket Lab's NASA Win Tests Key Support After Sharp Pullback 3 ETFs Pairing Market-Beating Returns With High Dividend Yields BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout 3 Stocks That Could Benefit as the Robotaxi Race Heats Up Palantir’s Valuation Problem Just Met 2 New Growth Catalysts Micron’s HBM Surge Could Redefine the AI Growth Story Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
